Ravulizumab Recruiting Phase 3 Trials for Paroxysmal Nocturnal Haemoglobinuria (PNH) Treatment

IndicationsStatusPurposePhase
RecruitingTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT03406507A Phase 3, Open-Label Study of ALXN1210 in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria (PNH)